Skip to content
Screener

Theravance Biopharma TBPH Q3 2025 earnings

Reported November 10, 2025 · After market close

Revenue$20.0MMiss by $23.1M
EPS$0.04Beat by $0.07
Revenue estimate$43.1M
EPS estimate-$0.03

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$22.0M
EPS estimate$0.24

Financials

Q3 2025

Income statement

See full
Revenue$20.0M+18.5%
Operating income-$6.5M+40.4%
Net income$3.6M+128%
EPS (diluted)$0.07+127%

Balance sheet

See full
Cash & equivalents$174.8M+648%
Total debt$44.6M-0.9%
Total equity$232.7M+25.3%
Total assets$415.5M+16.7%

Cash flow

See full
Free cash flow$59.6M+1,244%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$735.27M+87.1%
Enterprise value$605.1M+46.0%
P/E25.1×—
P/S9.2×+2.9×

Profitability

See full
Operating margin-40.9%-11.9pp
Net margin36.5%+21.7pp
FCF margin221.3%+205pp

Returns & leverage

See full
Return on equity14%+8.7pp
Debt / equity0.2×-0.1×
Current ratio9.5×+4.5×

Segments

By segment

See full
Single Reportable$20.0M+18.5%

By product

See full
Collaborative Arrangement Revenue$20.0M+18.5%

FAQ

When did Theravance Biopharma report Q3 2025 earnings?
Theravance Biopharma (TBPH) reported Q3 2025 earnings on November 10, 2025 after market close.
What were Theravance Biopharma's Q3 2025 revenue and EPS?
Theravance Biopharma reported revenue of $20.0M and eps of $0.04 for Q3 2025.
Did Theravance Biopharma beat estimates in Q3 2025?
Revenue missed the consensus estimate of $43.1M by $23.1M. EPS beat the consensus estimate of $-0.03 by $0.07.
How did Theravance Biopharma's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 18.5% from $16.9M a year earlier.
Where can I find Theravance Biopharma's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-109146) and the 10-Q periodic report (0001104659-25-110382) directly on SEC EDGAR. The filing index links above go to sec.gov.